VEGFR2/CD309 抗体
(VEGF Receptor 2 (VEGFR2))
Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. This gene encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc.. Mutations of this gene are implicated in infantile capillary hemangiomas. [provided by RefSeq, May 2009].
| Catalog no. | 产品 | 适用 | 宿主 / 克隆类型 | 应用 | 价格和交货时间 |
|---|---|---|---|---|---|
| VEGFR2/CD309 抗体 | 人 | 兔 Polyclonal |
|
|
|
| VEGFR2/CD309 抗体 (pTyr1214) | 人, 小鼠, 大鼠 | 兔 Polyclonal |
|
|
|
| VEGFR2/CD309 抗体 (pTyr1175) | 人, 小鼠, 大鼠 | 兔 Polyclonal |
|
|
|
| VEGFR2/CD309 抗体 (Ser7) | 人, 小鼠 | 兔 Polyclonal |
|
|
|
| VEGFR2/CD309 抗体 (N-Term) | 人, 犬 | 兔 Polyclonal |
|
|
|
| VEGFR2/CD309 抗体 (AA 46-320) | 人 | 兔 Polyclonal |
|
|
|
| VEGFR2/CD309 抗体 (AA 31-130) | 人 | 小鼠 Monoclonal |
|
|
|
| Recombinant VEGFR2/CD309 抗体 | 人 | Human Monoclonal |
|
|
|
| VEGFR2/CD309 抗体 (AA 20-242) | 人 | 兔 Polyclonal |
|
|
|
| VEGFR2/CD309 抗体 (N-Term) | 人, Pig, 犬, Cow, 马 | 兔 Polyclonal |
|
|
|
| VEGFR2/CD309 抗体 (AA 601-678) | 人 | 兔 Polyclonal |
|
|
|
| VEGFR2/CD309 抗体 (pTyr1175) | 人 | 兔 Polyclonal |
|
|
|
| VEGFR2/CD309 抗体 (PerCP-Cy5.5) | 小鼠 | 大鼠 Monoclonal |
|
|
|
| VEGFR2/CD309 抗体 | 小鼠 | 大鼠 Monoclonal |
|
|
|
| VEGFR2/CD309 抗体 (pTyr1175) | 人 | 兔 Polyclonal |
|
|
|
| VEGFR2/CD309 抗体 (AA 252-301) | 人, Pig, 犬, 猴, Cow, 马 | 兔 Polyclonal |
|
|
|
| VEGFR2/CD309 抗体 | 人 | 小鼠 Monoclonal |
|
|
|
| VEGFR2/CD309 抗体 (AA 8-290) | Pig | 兔 Polyclonal |
|
|
|
| VEGFR2/CD309 抗体 (AA 46-320) | 人 | 小鼠 Monoclonal |
|
|
|
| VEGFR2/CD309 抗体 (pTyr951) | 人, 小鼠, 大鼠 | 兔 Polyclonal |
|
|
Primary Antibody
- IHC (Immunohistochemistry: 有验证图片)
- ELISA (ELISA: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
Primary Antibody
- WB (Western Blotting: 有验证图片)
- IHC (Immunohistochemistry: 所列应用)
- ELISA (ELISA: 所列应用)
- IF (Immunofluorescence: 所列应用)
- 适用
- 人, 小鼠, 大鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- pTyr1214
Primary Antibody
- WB (Western Blotting: 有验证图片)
- IHC (Immunohistochemistry: 所列应用)
- ELISA (ELISA: 所列应用)
- 适用
- 人, 小鼠, 大鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- pTyr1175
Primary Antibody
- WB (Western Blotting: 有验证图片)
- IHC (Immunohistochemistry: 所列应用)
- ELISA (ELISA: 所列应用)
- IF (Immunofluorescence: 所列应用)
- 适用
- 人, 小鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- Ser7
Primary Antibody
- WB (Western Blotting: 有验证图片)
- IHC (Immunohistochemistry: 有验证图片)
- 适用
- 人, 犬
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗原表位
- N-Term
Primary Antibody
- WB (Western Blotting: 有验证图片)
- IHC (Immunohistochemistry: 有验证图片)
- IF (Immunofluorescence: 所列应用)
- ICC (Immunocytochemistry: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- AA 46-320
Primary Antibody
- ELISA (ELISA: 有验证图片)
- WB (Western Blotting: 有验证图片)
- 适用
- 人
- 宿主
- 小鼠
- 克隆形成能力
- Monoclonal
- 克隆
- 2A2
- 标记
- unconjugated
- 抗体亚型
- IgG2a
- 抗原表位
- AA 31-130
Primary Antibody
- SDS (SDS-PAGE: 有验证图片)
- SEC-HPLC (Size-exclusion chromatography-High Pressure Liquid Chromatography: 有验证图片)
- ELISA (ELISA: 所列应用)
- FACS (Flow Cytometry: 所列应用)
- Func (Functional Studies: 所列应用)
- BLI (Bio-Layer Interferometry: 所列应用)
- SPR (Surface Plasmon Resonance: 所列应用)
- 适用
- 人
- 宿主
- Human
- 克隆形成能力
- Monoclonal
- 标记
- unconjugated
- 蛋白类型
- Recombinant Antibody
- 抗体亚型
- IgG1
Primary Antibody
- WB (Western Blotting: 有验证图片)
- IHC (Immunohistochemistry: 有验证图片)
- IHC (p) (Immunohistochemistry (Paraffin-embedded Sections): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- AA 20-242
Primary Antibody
- WB (Western Blotting: 有验证图片)
- IHC (Immunohistochemistry: 有验证图片)
- 适用
- 人, Pig, 犬, Cow, 马
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗原表位
- N-Term
Primary Antibody
- WB (Western Blotting: 有验证图片)
- FACS (Flow Cytometry: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- AA 601-678
Primary Antibody
- IHC (Immunohistochemistry: 有验证图片)
- WB (Western Blotting: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- pTyr1175
Primary Antibody
- FACS (Flow Cytometry: 有验证图片)
- 适用
- 小鼠
- 宿主
- 大鼠
- 克隆形成能力
- Monoclonal
- 克隆
- Avas12a1
- 标记
- PerCP-Cy5.5
- 抗体亚型
- IgG2a kappa
Primary Antibody
- SDS (SDS-PAGE: 有验证图片)
- WB (Western Blotting: 所列应用)
- 适用
- 小鼠
- 宿主
- 大鼠
- 克隆形成能力
- Monoclonal
- 克隆
- DC101
- 标记
- unconjugated
- 抗体亚型
- IgG1, kappa
Primary Antibody
- DB (Dot Blot: 有验证图片)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 克隆
- RB25841
- 标记
- unconjugated
- 抗体亚型
- Ig Fraction
- 抗原表位
- pTyr1175
Primary Antibody
- FACS (Flow Cytometry: 有验证图片)
- WB (Western Blotting: 所列应用)
- IHC (Immunohistochemistry: 所列应用)
- ELISA (ELISA: 所列应用)
- 适用
- 人
- 宿主
- 小鼠
- 克隆形成能力
- Monoclonal
- 克隆
- EIC
- 标记
- unconjugated
- 抗体亚型
- IgG1
Primary Antibody
- WB (Western Blotting: 有验证图片)
- IF (Immunofluorescence: 所列应用)
- ICC (Immunocytochemistry: 所列应用)
- 适用
- Pig
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- AA 8-290
Primary Antibody
- WB (Western Blotting: 有验证图片)
- IF (Immunofluorescence: 所列应用)
- ICC (Immunocytochemistry: 所列应用)
- 适用
- 人
- 宿主
- 小鼠
- 克隆形成能力
- Monoclonal
- 克隆
- C5
- 标记
- unconjugated
- 抗体亚型
- IgG2b kappa
- 抗原表位
- AA 46-320
Primary Antibody
- IHC (p) (Immunohistochemistry (Paraffin-embedded Sections): 有验证图片)
- WB (Western Blotting: 所列应用)
- IHC (Immunohistochemistry: 所列应用)
- IF (Immunofluorescence: 所列应用)
- ICC (Immunocytochemistry: 所列应用)
- 适用
- 人, 小鼠, 大鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- pTyr951
Latest Publications for our VEGFR2/CD309 抗体
: "Comprehensive strategy of conduit guidance combined with VEGF producing Schwann cells accelerates peripheral nerve repair." in: Bioactive materials, Vol. 6, Issue 10, pp. 3515-3527, (2021) (PubMed).
: "Microvesicles from human adipose stem cells promote wound healing by optimizing cellular functions via AKT and ERK signaling pathways." in: Stem cell research & therapy, Vol. 10, Issue 1, pp. 47, (2020) (PubMed).
: "BA-12 Inhibits Angiogenesis via Glutathione Metabolism Activation." in: International journal of molecular sciences, Vol. 20, Issue 16, (2020) (PubMed).
: "Deletion of Nkx2-5 in trabecular myocardium reveals the developmental origins of pathological heterogeneity associated with ventricular non-compaction cardiomyopathy." in: PLoS genetics, Vol. 14, Issue 7, pp. e1007502, (2019) (PubMed).
: "Endothelial Calcineurin Signaling Restrains Metastatic Outgrowth by Regulating Bmp2." in: Cell reports, Vol. 26, Issue 5, pp. 1227-1241.e6, (2019) (PubMed).
: "A Short Bout of Exercise Prior to Stroke Improves Functional Outcomes by Enhancing Angiogenesis." in: Neuromolecular medicine, (2019) (PubMed).
: "Sox7 promotes high-grade glioma by increasing VEGFR2-mediated vascular abnormality." in: The Journal of experimental medicine, Vol. 215, Issue 3, pp. 963-983, (2019) (PubMed).
: "Treatment of diabetes mellitus-induced erectile dysfunction using endothelial progenitor cells genetically modified with human telomerase reverse transcriptase." in: Oncotarget, Vol. 7, Issue 26, pp. 39302-39315, (2018) (PubMed).
: "IL13Rα2 siRNA inhibited cell proliferation, induced cell apoptosis, and suppressed cell invasion in papillary thyroid carcinoma cells." in: OncoTargets and therapy, Vol. 11, pp. 1345-1352, (2018) (PubMed).
: "TRIM24 siRNA induced cell apoptosis and reduced cell viability in human nasopharyngeal carcinoma cells." in: Molecular medicine reports, Vol. 18, Issue 1, pp. 369-376, (2018) (PubMed).
: "Microvesicles from human adipose stem cells promote wound healing by optimizing cellular functions via AKT and ERK signaling pathways." in: Stem cell research & therapy, Vol. 10, Issue 1, pp. 47, (2020) (PubMed).
: "BA-12 Inhibits Angiogenesis via Glutathione Metabolism Activation." in: International journal of molecular sciences, Vol. 20, Issue 16, (2020) (PubMed).
: "Deletion of Nkx2-5 in trabecular myocardium reveals the developmental origins of pathological heterogeneity associated with ventricular non-compaction cardiomyopathy." in: PLoS genetics, Vol. 14, Issue 7, pp. e1007502, (2019) (PubMed).
: "Endothelial Calcineurin Signaling Restrains Metastatic Outgrowth by Regulating Bmp2." in: Cell reports, Vol. 26, Issue 5, pp. 1227-1241.e6, (2019) (PubMed).
: "A Short Bout of Exercise Prior to Stroke Improves Functional Outcomes by Enhancing Angiogenesis." in: Neuromolecular medicine, (2019) (PubMed).
: "Sox7 promotes high-grade glioma by increasing VEGFR2-mediated vascular abnormality." in: The Journal of experimental medicine, Vol. 215, Issue 3, pp. 963-983, (2019) (PubMed).
: "Treatment of diabetes mellitus-induced erectile dysfunction using endothelial progenitor cells genetically modified with human telomerase reverse transcriptase." in: Oncotarget, Vol. 7, Issue 26, pp. 39302-39315, (2018) (PubMed).
: "IL13Rα2 siRNA inhibited cell proliferation, induced cell apoptosis, and suppressed cell invasion in papillary thyroid carcinoma cells." in: OncoTargets and therapy, Vol. 11, pp. 1345-1352, (2018) (PubMed).
: "TRIM24 siRNA induced cell apoptosis and reduced cell viability in human nasopharyngeal carcinoma cells." in: Molecular medicine reports, Vol. 18, Issue 1, pp. 369-376, (2018) (PubMed).
Aliases for VEGFR2/CD309 抗体
kinase insert domain receptor (KDR) 抗体kinase insert domain protein receptor (Kdr) 抗体
kinase insert domain receptor (Kdr) 抗体
vascular endothelial growth factor receptor kdr-like (LOC100136647) 抗体
kinase insert domain receptor (a type III receptor tyrosine kinase) (KDR) 抗体
kinase insert domain receptor (a type III receptor tyrosine kinase) (kdr) 抗体
kinase insert domain receptor like (kdrl) 抗体
6130401C07 抗体
CD309 抗体
fk52c05 抗体
flk 抗体
Flk-1 抗体
FLK-1 抗体
flk-1 抗体
FLK/KDR 抗体
FLK1 抗体
Flk1 抗体
flk1 抗体
flk1b 抗体
KDR 抗体
kdr 抗体
kdra 抗体
kdrb 抗体
Krd-1 抗体
Ly73 抗体
si:busm1-205d10.1 抗体
si:ch211-254j6.1 抗体
si:ch211-278f21.4 抗体
sVEGFR-2 抗体
VEGFR 抗体
VEGFR-2 抗体
Vegfr-2 抗体
vegfr-2 抗体
VEGFR2 抗体
vegfr2 抗体
vegfr4 抗体
vegr2 抗体
wu:fc31a09 抗体
wu:fk52c05 抗体
您还需要查找其他产品吗？
- VEGFD 抗体
- VEGFC 抗体
- VEGFB 抗体
- VEGF121 抗体
- VEGF 抗体
- VDAC3 抗体
- VDAC2 抗体
- VDAC1 抗体
- VCX3A 抗体
- VCX 抗体
- Vcpip1 抗体
- Vcan 抗体
- VCAM1 抗体
- VBP1 抗体
- VAX2 抗体
- VAV3 抗体
- VAV2 抗体
- VAV1 抗体
- VAT1 抗体
- VASP 抗体
- Ventral Anterior Homeobox 1 抗体
- VENTX 抗体
- Very Low Density Lipoprotein 抗体
- Vesicle Transport Protein SFT2B 抗体
- Vesicle-Associated Membrane Protein 1 (Synaptobrevin 1) 抗体
- Vestigial 抗体
- Vestigial Like 2 抗体
- VEZF1 抗体
- VEZT 抗体
- VGF 抗体
- VGLL1 抗体
- VGLL3 抗体
- VGLL4 抗体
- VHL 抗体
- VHLL 抗体
- VILL 抗体
- Villin 1 抗体
- Vimentin 抗体
- Vinculin 抗体
- Vinexin 抗体
You are here:
